Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Kochenderfer, James N., Dudley, Mark E., Kassim, Sadik H., Somerville, Robert P.T., Carpenter, Robert O., Stetler-Stevenson, Maryalice, Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Sherry, Richard M., Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F., Ngo, Lien T., Goy, Andre, Feldman, Tatyana, Spaner, David E., Wang, Michael L., Chen, Clara C., Kranick, Sarah M., Nath, Avindra, Nathan, Debbie-Ann N., Morton, Kathleen E., Toomey, Mary Ann, Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
https://ncbi.nlm.nih.gov/pubmed/25154820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados